ImpediMed Ltd
ASX:IPD
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
ImpediMed Ltd
ASX:IPD
|
AU |
|
Gold Royalty Corp
F:6LS0
|
CA |
|
Miller Industries Inc
F:5OJ
|
US |
|
B
|
Brooker Group PCL
SET:BTC
|
TH |
|
Axos Financial Inc
NYSE:AX
|
US |
|
R
|
Rai Way SpA
F:4RW
|
IT |
|
Modern Internasional Tbk PT
IDX:MDRN
|
ID |
|
J
|
JD.com Inc
XMUN:013C
|
CN |
Ergebniskonferenzen
Letzter Earnings Call
Execution: Management said sales improved quarter on quarter, with 40 units sold, but still fell short of plan and the team is not satisfied with the pace of conversion.
Reimbursement: National coverage rose to 95%, or 331 million covered lives, which management said should help both new customer wins and reengagement with existing accounts.
Funding: The company raised $15.3 million in the quarter and used $5 million to partially repay debt, leaving a cash balance of $15.3 million.
Cost control: Leadership highlighted a $5 million annualized operating cost reduction and said savings should flow through at about $1 million to $1.5 million per quarter.
Growth areas: The company is pushing growth in cancer survivorship, heart failure monitoring, and body composition/weight management, with management emphasizing disciplined commercial execution over hype.